India Pharmaceutical Manufacturing Market Size, Share & Trends Analysis Report by Dosage Form (Tablets, Injectables), Manufacturing Type (In-house, Contract), Therapeutic Category (Endrocrinology, Cardiovascular), and Segment Forecasts, 2024-2030

1.1 Market Segmentation
1.1.1 Market Definitions
1.1.2 Estimates and Forecast Timeline
1.2 Objectives
1.3 Research Methodology
1.4 Information Procurement
1.4.1 Purchased Database
1.4.2 Internal Database
1.4.3 Secondary Sources
1.4.4 Primary Research
1.4.5 Details of Primary Research
1.5 Information or Data Analysis
1.5.1 Data Analysis Models
1.6 Market Formulation & Validation
1.7 Model Details
1.7.1 Commodity Flow Analysis
1.7.1.1 Approach 1: Commodity Flow Approach
1.7.1.2 Approach 2: Country Wise Market Estimation Using Bottom-up Approach
1.8 List of Secondary Sources
1.9 List of Abbreviations

2.1 Market Snapshot
2.2 Dosage Form and Manufacturing Type Snapshot
2.3 Therapeutic Category Segment Snapshot
2.4 Competitive Landscape Snapshot

3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.1.1 Global Pharmaceutical Market
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.1.1 Rising Pharmaceutical R&D Spending
3.2.1.2 Advancements in Pharmaceutical Manufacturing Technologies
3.2.1.3 Rising Geriatric Population and Prevalence of Chronic Disorders
3.2.2 Market Restraint Analysis
3.2.2.1 Challenges in Pharma Supply Chain
3.2.2.2 Inadequate Training and Motivation for Research and Innovations Efforts
3.3 Market Analysis Tools
3.3.1 Industry Analysis: Porter's Five Forces
3.3.2 Macroeconomic Analysis
3.4 Current & Future Market Opportunity Analysis
3.4.1 Current Opportunity Analysis
3.4.1.1 Increase in Clinical Trials
3.4.1.2 Increasing Investment and Funding in Pharmaceutical it
3.4.2 the Future of Indian Manufacturing
3.5 Queries/Request Raised by CMOs
3.6 List of Key 5 Solid Dosage Drugs for Each Therapeutic Area

4.1 India Pharmaceutical Manufacturing Market: Dosage Form Movement Analysis
4.2 India Pharmaceutical Manufacturing Market Estimates & Forecast, by Dosage Form (USD Million)
4.3 Penetration & Growth Prospect Mapping for Dosage Form, 2023
4.3.1 Tablets
4.3.1.1 Tablets Market, 2018-2030 (USD Million)
4.3.2 Capsules
4.3.2.1 Capsules Market, 2018-2030 (USD Million)
4.3.2.2.1 Soft Gelatin Capsule
4.3.2.2.1.1 Soft Gelatin Capsules Market, 2018-2030 (USD Million)
4.3.2.3.1 Hard Gelatin Capsules
4.3.1.3.1.1 Hard Gelatin Capsules Market, 2018-2030 (USD Million)
4.3.2.4.1 Others
4.3.2.4.1.1 Others Market, 2018-2030 (USD Million)
4.3.3 Injectables
4.3.3.1 Injectables Market, 2018-2030 (USD Million)
4.3.4 Others
4.3.4.1 Others Market, 2018-2030 (USD Million)

5.1 India Pharmaceutical Manufacturing Market: Manufacturing Type Movement Analysis
5.2 India Pharmaceutical Manufacturing Market Estimates & Forecast, by Manufacturing Type (USD Million)
5.3 Penetration & Growth Prospect Mapping for Manufacturing Type, 2023
5.3.1 in-HOUSE MANUFACTURING
5.3.1.1 in-house MAnufacturing Market, 2018-2030 (USD Million)
5.3.2 CONTRACT MANUFACTURING
5.3.2.1 Contract Manufacturing Market, 2018-2030 (USD Million)

6.1 India Pharmaceutical Manufacturing Market: Therapeutic Category Movement Analysis
6.2 India Pharmaceutical Manufacturing Market Estimates & Forecast, by Therapeutic Category (USD Million)
6.3 Penetration & Growth Prospect Mapping for Therapeutic Category, 2023
6.4 Endocrinology
6.4.1 Canagliflozin
6.4.1.1 Approval
6.4.1.2 Patent Expiry
6.4.1.3 Available Combinations
6.4.1.4 Countries the Drug is Available in
6.4.1.5 Trends
6.4.2 Empagliflozin
6.4.2.1 Approval
6.4.2.2 Patent Expiry
6.4.2.3 Available Combinations
6.4.2.4 Countries Drug Available in
6.4.2.5 Trends
6.4.3 Semaglutide
6.4.3.1 Approval
6.4.3.2 Patent Expiry
6.4.3.3 Available Combinations
6.4.3.4 Countries Drug Available in
6.4.3.5 Trends
6.4.4 Tirzepatide
6.4.4.1 Approval
6.4.4.2 Patent Expiry
6.4.4.3 Available Combinations
6.4.4.4 Countries Drug Available in
6.4.4.5 Trends
6.4.5 Linagliptin
6.4.5.1 Approval
6.4.5.2 Patent Expiry
6.4.5.3 Available Combinations
6.4.5.4 Countries Drug Available in
6.4.5.5 Trends
6.4.6 Alogliptin
6.4.6.1 Approval
6.4.6.2 Patent Expiry
6.4.6.3 Available Combinations
6.4.7 Trelagliptin
6.4.8 Myo-Inositol
6.5 Cardiovascular
6.5.1 Treprostinil
6.5.1.1 Approval
6.5.1.2 Patent Expiry
6.5.1.3 Available Combinations
6.5.1.4 Trends
6.5.2 Azilsartan
6.5.2.1 Approval
6.5.2.2 Patent Expiry
6.5.2.3 Available Combinations
6.5.3 Azilsartan+Amlodipine
6.5.4 Amlodipine + Lisinopril
6.5.5 Sparsentan
6.5.5.1 Approval
6.5.5.2 Patent Expiry
6.5.5.3 Available Combinations
6.5.6 Esaxerenone
6.5.6.1 Approval
6.5.6.2 Available Combinations
6.6 CNS
6.6.1 Cariprazine
6.6.1.1 Approval
6.6.1.2 Patent Expiry
6.6.1.3 Available Combinations
6.6.1.4 Countries Drug Available in
6.6.1.5 Trends
6.6.2 Brexpiprazole
6.6.2.1 Approval
6.6.2.2 Patent Expiry
6.6.2.3 Available Combinations
6.6.2.4 Trends
6.6.3 Lisdexamfetamine
6.6.3.1 Approval
6.6.3.2 Patent Expiry
6.6.3.3 Available Combinations
6.6.3.4 Trends
6.6.4 Vortioxetine
6.6.4.1 Approval
6.6.4.2 Patent Expiry
6.6.4.3 Available Combinations
6.6.4.4 Countries Drug Available in
6.6.4.5 Trends
6.6.5 Mirogabalin Besylate
6.6.6 Lasmiditan
6.6.6.1 Approval
6.6.6.2 Patent Expiry
6.6.6.3 Available Combinations
6.6.6.4 Trends
6.6.7 Siponimod
6.6.7.1 Approval
6.6.7.2 Patent Expiry
6.6.7.3 Available Combinations
6.6.7.4 Trends
6.7 Analgesics
6.7.1 Ibuprofen+Famotidine
6.7.2 Upadacitinib
6.7.2.1 Approval
6.7.2.2 Patent Expiry
6.7.2.3 Available Combinations
6.7.2.4 Countries Drug Available in
6.7.2.5 Trends
6.8 Antacid
6.8.1 Pantoprazole Gastro Resistant
6.8.1.1 Approval
6.8.1.2 Patent Expiry
6.9 Antibiotic
6.9.1 Doxycycline
6.9.1.1 Approval
6.9.1.2 Patent Expiry
6.9.1.3 Available Combinations
6.9.2 Tedizolid
6.10 Antifungal
6.10.1 Posaconazole
6.10.1.1 Approval
6.10.1.2 Patent Expiry
6.10.1.3 Available Combinations
6.11 Antiprotozoal
6.11.1 Nitazoxanide
6.11.1.1 Approval
6.11.1.2 Patent Expiry
6.11.1.3 Available Combinations
6.12 Hematology
6.12.1 Lenalidomide
6.12.1.1 Approval
6.12.1.2 Patent Expiry
6.12.1.3 Available Combinations
6.12.1.4 Trends
6.12.2 Daprodustat
6.12.2.1 Approval
6.12.2.2 Patent Expiry
6.12.2.3 Available Combinations
6.12.2.4 Trends
6.12.3 Roxadustat
6.12.3.1 Approval
6.12.3.2 Available Combinations
6.12.3.3 Countries Drug Available in
6.12.4 Edoxaban
6.12.4.1 Approval
6.12.4.2 Patent Expiry
6.12.4.3 Available Combinations
6.12.4.4 Countries Drug Available in
6.12.4.5 Trends
6.12.5 Avatrombopag
6.12.5.1 Approval
6.12.5.2 Available Combinations
6.12.5.3 Trends
6.13 Others
6.13.1 Linaclotide
6.13.1.1 Approval
6.13.1.2 Patent Expiry
6.13.1.3 Available Combinations
6.13.1.4 Trends
6.13.2 Apremilast
6.13.2.1 Approval
6.13.2.2 Patent Expiry
6.13.2.3 Available Combinations
6.13.2.4 Trends
6.13.3 Tegoprazan
6.13.4 Suvorexant
6.13.4.1 Approval
6.13.4.2 Patent Expiry
6.13.4.3 Available Combinations
6.13.4.4 Trends
6.13.5 Vonoprazan
6.13.5.1 Approval
6.13.5.2 Patent Expiry
6.13.5.3 Available Combinations
6.13.5.4 Trends
6.13.6 Rolapitant
6.13.6.1 Approval
6.13.6.2 Patent Expiry
6.13.6.3 Available Combinations
6.13.7 Elagolix
6.13.7.1 Approval
6.13.7.2 Patent Expiry
6.13.7.3 Available Combinations
6.13.7.4 Trends

7.1 List of Cancer Molecules Going Off Patent Between 2023 and 2030
7.2 Global Overview
7.3 Market Opportunities, by Type of Cancer

8.1 Complete India Market Overview
8.2 Exports in Injectable Formulation
8.2.1 by Therapeutic Category
8.2.1.1 Endocrinology
8.2.1.2 Cardiovascular
8.2.1.3 CNS
8.2.1.4 Analgesics
8.2.1.5 Antacid
8.2.1.6 Antibiotic
8.2.1.7 Antifungal
8.2.1.8 Antiprotozoal
8.2.1.9 Hematology
8.2.1.10 Others
8.2.2 by Dosage Form
8.2.2.1 Intravenous
8.2.2.2 Subcutaneous
8.2.2.3 Intramuscular
8.2.2.4 Others

9.1 Participants’ Overview
9.2 Financial Performance
9.3 Public Players Financial Overview
9.3.1 Alkem Laboratories Ltd.
9.3.1.1 Alkem's Performance in Key Therapeutic Segments
9.3.1.2 Performance of Alkem’s Top 10 Brands
9.3.2 Sun Pharmaceutical Industries Ltd.
9.3.2.1 India Business Therapeutic Revenue Break-Up
9.3.2.2 Business-Wise Revenue Share
9.3.3 Ajanta Pharma Ltd.
9.3.3.1 Focused Presence in Key Therapy Areas
9.3.4 Cipla Inc.
9.3.4.1 Manufacturing Capabilities Highlights (in Million Units) FY 2022-23
9.3.4.2 Global Presence
9.3.4.3 Branded Prescription Business
9.3.4.4 API Manufacturing Capability
9.3.5 Eris Lifesciences
9.3.5.1 Eris Lifesciences Performance in Key Therapeutic Segments
9.3.6 Lupin
9.3.6.1 Lupin’s Therapy-Wise Ranking
9.3.7 Glenmark Pharmaceuticals Ltd.
9.3.7.1 Revenue Distribution by Geographies
9.3.7.2 Top Brands of Glenmark in Top 300 of IPM
9.3.8 Torrent Pharmaceuticals Ltd.
9.3.8.1 Revenue Distribution by Geographies
9.4 Participant Categorization
9.4.1 Key Company Market Share Analysis
9.4.2 Strategy Mapping
9.4.2.1 Acquisition
9.4.2.2 Partnership & Collaborations
9.4.2.3 Product Launches
9.4.2.4 Expansion
9.4.2.5 Others (Investment, Divestment, Market Penetration, Funding, & Approval)
9.5 List of Key CMOs

Table 1 List of Abbreviation
Table 2 List of Data Points Generally Requested by the Indian CMOs from Grand View Research Inc.
Table 3 India Pharmaceutical Manufacturing Market Revenue Estimates and Forecast, by Dosage Form, 2018-2030 (USD Million)
Table 4 India Pharmaceutical Manufacturing Market Revenue Estimates and Forecast, by Manufacturing Type, 2018-2030 (USD Million)
Table 5 India Pharmaceutical Manufacturing Market Revenue Estimates and Forecast, by Therapeutic Category, 2018-2030 (USD Million)
Table 6 Patent Expiry Data for Approved Formulation:
Table 7 Brand Name/prescription Products:
Table 8 Combinations Products:
Table 9 Patent Expiry Data for Approved Formulation:
Table 10 Brand Name/prescription Products:
Table 11 Combinations Products:
Table 12 Patent Expiry Data for Approved Formulation:
Table 13 Brand Name/prescription Products:
Table 14 Patent Expiry Data for Approved Formulation:
Table 15 Brand Name/prescription Products:
Table 16 Patent Expiry Data for Approved Formulation:
Table 17 Brand Name/prescription Products:
Table 18 Combinations Products:
Table 19 Patent Expiry Data for Approved Formulation:
Table 20 Brand Name/prescription Products:
Table 21 Generic Products:
Table 22 Combinations Products:
Table 23 Patent Expiry Data for Approved Formulation:
Table 24 Brand Name/prescription Products:
Table 25 Generic Products:
Table 26 Combination Products:
Table 27 Patent Expiry Data for Approved Formulation:
Table 28 Brand Name/prescription Products:
Table 29 Combinations Products:
Table 30 Patent Expiry Data for Approved Formulation:
Table 31 Brand Name/prescription Products:
Table 32 Brand Name/prescription Products:
Table 33 Patent Expiry Data for Approved Formulation:
Table 34 Brand Name/prescription Products:
Table 35 Combinations Products:
Table 36 Patent Expiry Data for Approved Formulation:
Table 37 Brand Name/prescription Products:
Table 38 Generic Products:
Table 39 Combinations Products:
Table 40 Patent Expiry Data for Approved Formulation:
Table 41 Brand Name/prescription Products:
Table 42 Generic Products:
Table 43 Patent Expiry Data for Approved Formulation:
Table 44 Brand Name/prescription Products:
Table 45 Patent Expiry Data for Approved Formulation:
Table 46 Brand Name/prescription Products:
Table 47 Patent Expiry Data for Approved Formulation:
Table 48 Brand Name/prescription Products:
Table 49 Patent Expiry Data for Approved Formulation:
Table 50 Brand Name/prescription Products:
Table 51 Patent Expiry Data for Approved Formulation:
Table 52 Patent Expiry Data for Approved Formulation:
Table 53 Brand Name/prescription Products:
Table 54 Unapproved Products:
Table 55 Patent Expiry Data for Approved Formulation:
Table 56 Brand Name/prescription Products:
Table 57 Generic Products:
Table 58 Patent Expiry Data for Approved Formulation:
Table 59 Brand Name/prescription Products:
Table 60 Generic Products:
Table 61 Patent Expiry Data for Approved Formulation:
Table 62 Brand Name/prescription Products:
Table 63 Generic Products:
Table 64 Patent Expiry Data for Approved Formulation:
Table 65 Brand Name/prescription Products:
Table 66 Brand Name/prescription Products:
Table 67 Patent Expiry Data for Approved Formulation:
Table 68 Brand Name/prescription Products:
Table 69 Brand Name/prescription Products:
Table 70 Patent Expiry Data for Approved Formulation:
Table 71 Brand Name/prescription Products:
Table 72 Patent Expiry Data for Approved Formulation:
Table 73 Brand Name/prescription Products:
Table 74 Generic Products:
Table 75 Combinations Products:
Table 76 Patent Expiry Data for Approved Formulation:
Table 77 Brand Name/prescription Products:
Table 78 Patent Expiry Data for Approved Formulation:
Table 79 Combinations Products:
Table 80 Patent Expiry Data for Approved Formulation:
Table 81 Brand Name/prescription Products:
Table 82 Patent Expiry Data for Approved Formulation:
Table 83 Brand Name/prescription Products:
Table 84 Combinations Products:
Table 85 Opportunities for Generic Manufacturers
Table 86 Opportunities for Branded Manufacturers

Figure 1 India Pharmaceutical Manufacturing Market Segmentation
Figure 2 Market Research Process
Figure 3 Data Triangulation Techniques
Figure 4 Primary Research Pattern
Figure 5 Market Research Approaches
Figure 6 Value Chain Based Sizing & Forecasting
Figure 7 QFD Modelling for Market Share Assessment
Figure 8 Market Formulation & Validation
Figure 9 Market Snapshot
Figure 10 Dosage Form and Manufacturing Type Segment Snapshot
Figure 11 Therapeutic Category Segment Snapshot
Figure 12 Competitive Landscape Snapshot
Figure 13 Pharmaceuticals Market Value, 2023 (USD Million)
Figure 14 Market Dynamics
Figure 15 India Product Flow
Figure 16 Porter's Five Forces Analysis
Figure 17 PESTLE Analysis
Figure 18 India Pharmaceutical Manufacturing Market: Product Outlook and Key Takeaways
Figure 19 India Pharmaceutical Manufacturing Market: Dosage Form Movement Analysis
Figure 20 Penetration & Growth Prospect Mapping for Dosage Form, 2023
Figure 21 Tablets Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 22 Capsules Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 23 Soft Gelatin Capsule Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 24 Hard Gelatin Capsules Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 25 Others Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 26 Injectables Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 27 Others Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 28 India Pharmaceutical Manufacturing Market: Manufacturing Type Outlook and Key Takeaways
Figure 29 India Pharmaceutical Manufacturing Market: Manufacturing Type Movement Analysis
Figure 30 Penetration & Growth Prospect Mapping for Manufacturing Type, 2023
Figure 31 in-house Manufacturing Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 32 Advantages of in-house CRO & CMO
Figure 33 Contract Manufacturing Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 34 Contract Manufacturing Activities
Figure 35 India Pharmaceutical Manufacturing Market: Therapeutic Category Outlook and Key Takeaways
Figure 36 India Pharmaceutical Manufacturing Market: Therapeutic Category Movement Analysis
Figure 37 Penetration & Growth Prospect Mapping for Therapeutic Category, 2023
Figure 38 Endocrinology Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 39 Canagliflozin Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 40 Empagliflozin Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 41 Semaglutide Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 42 Tirzepatide Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 43 Linagliptin Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 44 Alogliptin Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 45 Trelagliptin Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 46 Myo-inositol Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 47 Cardiovascular Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 48 Treprostinil Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 49 Azilsartan Medoxomil Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 50 Azilsartan+Amlodipine Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 51 Amlodipine + Lisinopril Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 52 Sparsentan Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 53 Esaxerenone Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 54 CNS Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 55 Cariprazine Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 56 Brexpiprazole Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 57 Lisdexamfetamine Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 58 Vortioxetine Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 59 Mirogabalin Besylate Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 60 Lasmiditan Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 61 Siponimod Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 62 Analgesics Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 63 Ibuprofen+Famotidine Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 64 Upadacitinib Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 65 Antacid Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 66 Pantoprazole Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 67 Antibiotic Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 68 Doxycycline Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 69 Tedizolid Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 70 Antifungal Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 71 Posaconazole Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 72 Antiprotozoal Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 73 Nitazoxanide Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 74 Hematology Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 75 Lenalidomide Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 76 Daprodustat Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 77 Roxadustat Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 78 Edoxaban Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 79 Avatrombopag Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 80 Others Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 81 Linaclotidemarket Estimates and Forecast, 2018-2030 (USD Million)
Figure 82 Apremilast Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 83 Tegoprazan Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 84 Suvorexant Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 85 Vonoprazan Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 86 Rolapitant Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 87 Elagolix Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 88 Global Oncology Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 89 Oncology Opportunities
Figure 90 India Injectable Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 91 Endocrinology Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 92 Cardiovascular Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 93 CNS Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 94 Analgesics Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 95 Antacid Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 96 Antibiotic Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 97 Antifungal Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 98 Antiprotozoal Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 99 Hematology Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 100 Others Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 101 Intravenous Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 102 Subcutaneous Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 103 Intramuscular Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 104 Others Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 105 Company/competition Categorization
Figure 106 Key Company Market Share Analysis, 2023
Figure 107 Strategy Mapping